Use of eptifibatide as a bridge antiplatelet agent for intrathecal drug delivery system placement

Pain Physician

Volumn 15, Issue 6, 2012, Pages 479-483

  Sisk, Joseph ^a   Palma, Michael ^a   Cooper, Christopher ^a   Eltahawy, Ehab ^a   Atalla, Joseph ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Antiplatelet agents; Eptifibatide; Intrathecal drug delivery system; Pain

Indexed keywords

CLOPIDOGREL; EPTIFIBATIDE; PRASUGREL;

ADULT; ANALGESIA; ARTICLE; CASE REPORT; CONSERVATIVE TREATMENT; CONSULTATION; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG USE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTRATHECAL DRUG DELIVERY SYSTEM; MALE; MEDICAL HISTORY; OUTPATIENT CARE; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; SPINAL CORD STIMULATION; STENT THROMBOSIS; THORAX PAIN; THROMBOCYTE COUNT; TREATMENT FAILURE;

CORONARY ARTERY DISEASE; HUMANS; INFUSION PUMPS, IMPLANTABLE; MALE; MIDDLE AGED; PEPTIDES; PERIPHERAL NERVOUS SYSTEM DISEASES; PLATELET AGGREGATION INHIBITORS; STENTS; THROMBOSIS;

EID: 84869763905     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gurbel P, DiChiara J, Tantry U. Antiplatelet therapy after implantation of drugeluting stents: Duration, resistance, alternatives, and management of surgical patients. Am J Cardiol 2007; 100:18M 25M.
2. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D, Hirsh J, Husted S, Kvasnicka J, Montalescot G, García Rodríguez LA, Verheugt F, Vermylen J, Wallentin L, Priori SG, Alonso Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernández Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Morais J, Deckers J, Ferreira R, Mazzotta G, Steg PG, Teixeira F, Wilcox R; European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004; 25:166 181.
3. Hodgson J, Stone G, Lincoff A, Klein L, Walpole H, Bottner R, Weiner B, Leon, MB, Feldman T, Babb J, Dehmer G. Late stent thrombosis: Considerations and practical advice for the use of drug-eluting stents: A report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force. Catheter Cardiovasc Interv 2007; 69:327-333.
4. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi G, Stankovic G, Airoldi F, Chieffo A, Montorfanno M, Carlino M, Michev I, Corvaja N, Brigiori C, Gerckens U, Grube E Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126 2130.
5. Jang I, Gold H, Ziskind A, Fallon J, Holt R, Leinbach R, May J, Colleen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79:920-928.
6. Kuchulakanti P, Chu W, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents. Circulation 2006; 113:1108 1113.
7. Lüscher T, Steffel J, Eberli F, Joner M. Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation. 2007; 115:1051-1058
8. Schuhlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wejinger A, Pache J, Hadamitzky M, Schomig A. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998; 98:104 111.
9. Auer J, Berent R, Weber T, Eber B. Risk of noncardiac surgery in the months following placement of a drug-eluting coronary stent. J Am Coll Cardiol 2004; 43:713; author reply 4 5.
10. Artang R, Dieter R. Analysis of 36 reported cases of late thrombosis in drugeluting stents placed in coronary arteries. Am J Cardiol 2007; 99:1039 1043.
11. Cutlip D, Baim D, Ho K, Popma J, Lansky A, Cohen D, Carrozza J, Chauhan M, Rodriguez O, Kuntz R. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967 1971.
12. Kaluza G, Joseph J, Lee J, Raizner M, Raizner A. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35:1288-1294.
13. Murphy J, Fahy B. Thrombosis of sirolimus-eluting coronary stent in the postanesthesia care unit. Anesth Analg 2005; 101:971 973.
14. Park D, Park S, Park K, Lee B, Kim Y, Lee C, Hong M, Kim J, Park S. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98:352 356.
15. Satler L. Recommendations regarding stent selection in relation to the timing of noncardiac surgery postpercutaneous coronary intervention. Catheter Cardiovasc Interv 2004; 63:146 147.
16. Grines C, Bonow R, Casey D Jr, Gardner T, Lockhart P, Moliterno D, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49:734 739.
17. Brandt J, Payne C, Wiviott S, Wiviott, G, Weerakkody G, Farid N, Small D, Jakubowski J, Naganuma H, Winters K. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153:66. e9-16.
18. Mega J, Close S, Wiviott S, Shen L, Hockett R, Brandt J, Walkter J, Antman E, Macias W, Braunwald E, Sabatine M. Cytochrome p450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 2009; 119:2553-2560.
19. Frishman W, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995; 130:877 892.
20. Faulds D, Sorkin E. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994; 48:583 598.
21. Kleiman N. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am Heart J 1999; 138:263 275.
22. Morrison T, Horst B, Brown M, Bell M, Daniels P. Bridging with glycoprotein iib/iiia inhibitors for periprocedural management of antiplatelet therapy in patient with drug eluting stents. Catheter Cardiovasc Interv 2012; 79:575-582.
23. Rassi A, Blackstone E, Militello M, Theodos G, Cavender M, Sun Z, Ellis S, Cho L. Safety of "bridging" with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery. Am J Cardiol 2012; 110:485-90. Epub May 15.
24. Wessler J, Saldana F, Giugliano R. Bridging therapy after recent stent implantation: case report and review of data. Cardiovasc Revasc Med 2011; 13:30-38.
25. Roth E, Purnell C, Shabalov O, Mogullansky, D, Hernandez C. Elnicki M. Perioperative management of a patient with recently placed drug-eluting stents requiring urgent spinal surgery. J Gen Intern Med 2012; 27:10801083.
26. Horlocker T, Wedel D, Rowlingson J, Enneking F. Executive summary: Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35:102-105.
27. Horlocker T, Wedel D, Rowlingson J, Enneking F, Kopp S, Benzon H, Brown D, Heit J, Mulroy M, Rosenquist R, Tryba M, Yuan C. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35:64-101. (28) Green L, Machin S. Managing anticoagulated patients during neuraxial anaesthesia. Br J Haemato 2010; 149:195 208.